Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

Cobicistat-boosted darunavir plus tenofovir alafenamide (TAF) and emtricitabine (FTC) yielded less bone and renal toxicity than darunavir/cobicistat plus tenofovir/emtricitabine (TDF/FTC) in randomized a phase 2 trial.

Published
6 hours ago
From
NATAP
Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla [1]. All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.

Published
6 hours ago
From
NATAP
Drug use strongly associated with sex, condomless sex and STIs in gay men living with HIV in England

A large survey of gay and bisexual men living with HIV and attending eight sexual health clinics in England has found that half of them had used

Published
6 hours ago
By
Gus Cairns
Sharon Lewin appointed to lead Doherty Institute for Infection and Immunity

Leading infectious disease expert Professor Sharon Lewin has been appointed the inaugural Director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne.

Published
15 September 2014
From
Peter Doherty Institute
Long acting HIV drugs to be developed

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

Published
15 September 2014
From
University of Liverpool press release
Change to recommended regimen for post-exposure prophylaxis (PEP)

The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

Published
11 September 2014
From
Expert Advisory Group on AIDS (EAGA)
A "Bad Year" for HIV Cure Research? Experts Mix Realism and Hope

At ICAAC 2014, a major gathering of infectious disease experts, we heard speeches and spoke with leading HIV researchers about their evolving feelings regarding our fraught pathway toward a cure and the efforts currently underway to get us there.

Published
11 September 2014
From
The Body Pro
New medicines in development give hope to patients with HIV/AIDS

America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Published
11 September 2014
From
Pharmaceutical Research and Manufacturers of America
SIV Reservoir Fills Before Viremia in Rectally Infected Monkeys

In macaques rectally infected with simian immunodeficiency virus (SIV), the latent viral reservoir starts to fill with proviral DNA before viral RNA can be detected in peripheral blood. Findings from this study could help explain why HIV rebounded in the Mississippi child after being undetected for over 2 years.

Published
11 September 2014
From
International AIDS Society
Pregnant women need more support on looking after their own health after childbirth – could help retention in Option B+ programmes

Many women living with HIV believe that HIV care for the mother’s own health is unimportant once the baby is born, especially if the infant tests HIV

Published
10 September 2014
By
Roger Pebody
← First12345...364Next →

Filter by country